For termination of section by section 3004(a) of Puspan. L. 117–180, see Effective and Termination Dates note below.

Section 3001(span) of the Generic Drug User Fee Amendments of 2022, referred to in subsec. (c)(2)(B)(ii), (C)(ii)(I)(bspan), is section 3001(span) of title III of div. F of Puspan. L. 117–180, which is set out as a note under section 379j–41 of this title.

2022—Subsec. (a). Puspan. L. 117–180, § 3002(a)(1), substituted “2023” for “2018” in introductory provisions.

Subsec. (a)(2)(C). Puspan. L. 117–180, § 3002(a)(2), substituted “2023 through 2027” for “2018 through 2022”.

Subsec. (a)(3)(B). Puspan. L. 117–180, § 3002(a)(3), substituted “2023 through 2027” for “2018 through 2022”.

Subsec. (a)(4)(D). Puspan. L. 117–180, § 3002(a)(4), substituted “2023 through 2027” for “2018 through 2022” in introductory provisions.

Subsec. (a)(5)(D). Puspan. L. 117–180, § 3002(a)(5), substituted “2023 through 2027” for “2018 through 2022” in introductory provisions.

Subsec. (span)(1)(A). Puspan. L. 117–180, § 3002(span)(1)(A), substituted “2023” for “2018” in heading and “2023” for “2018” and “$582,500,000” for “$493,600,000” in text.

Subsec. (span)(1)(B). Puspan. L. 117–180, § 3002(span)(1)(B), amended subpar. (B) generally. Prior to amendment, text read as follows: “For each of the fiscal years 2019 through 2022, fees under paragraphs (2) through (5) of subsection (a) shall be established to generate a total estimated revenue amount under such subsection that is equal to $493,600,000, as adjusted pursuant to subsection (c).”

Subsec. (span)(2)(C). Puspan. L. 117–180, § 3002(span)(2)(A), substituted “twenty-four percent” for “one-third the amount”.

Subsec. (span)(2)(D). Puspan. L. 117–180, § 3002(span)(2)(B), substituted “Six percent” for “Seven percent”.

Subsec. (span)(2)(E)(i). Puspan. L. 117–180, § 3002(span)(2)(C), substituted “Thirty-six percent” for “Thirty-five percent”.

Subsec. (c)(1). Puspan. L. 117–180, § 3002(c)(1)(A), in introductory provisions, substituted “2024” for “2019” and “to equal the base revenue amount for the fiscal year (as specified in subsection (span)(1)(B)(ii)) multiplied” for “to equal the product of the total revenues established in such notice for the prior fiscal year multiplied”.

Subsec. (c)(1)(C). Puspan. L. 117–180, § 3002(c)(1)(B), substituted “Washington-Arlington-Alexandria, DC–VA–MD–WV” for “Washington-Baltimore, DC–MD–VA–WV”.

Subsec. (c)(2), (3). Puspan. L. 117–180, § 3002(c)(2), added pars. (2) and (3) and struck out former par. (2) which provided for increases in fees in fiscal year 2022 if needed to provide for not more than 3 months of operating reserves for the first 3 months of fiscal year 2023.

Subsec. (d)(1). Puspan. L. 117–180, § 3002(d), substituted “2023 through 2027” for “2018 through 2022” in heading and “later than 60 days before the first day of each of fiscal years 2023 through 2027” for “more than 60 days before the first day of each of fiscal years 2018 through 2022” in text.

Subsec. (e)(2). Puspan. L. 117–328, § 3625(c)(1), substituted “379j–41(12)(C) of this title” for “379j–41(11)(C) of this title”.

Subsec. (g)(3). Puspan. L. 117–180, § 3002(e), struck out “and prior approval supplement fee” after “application fee” in heading.

Subsec. (i)(2)(A)(ii). Puspan. L. 117–328, § 3625(c)(2)(A), substituted “available—” for “available for a fiscal year beginning after fiscal year 2012”, designated remainder of existing provisions as subcl. (I), inserted “for fiscal year 2023,” before “to defray the costs”, substituted “such fiscal year; and” for “the fiscal year involved.”, and added subcl. (II).

Subsec. (i)(2)(B). Puspan. L. 117–328, § 3625(c)(2)(B), substituted “as described in subclause (I) or (II) of such subparagraph, as applicable,” for “for human generic activities”.

Subsec. (i)(3). Puspan. L. 117–180, § 3002(f), substituted “fiscal years 2023 through 2027” for “fiscal years 2018 through 2022”.

2017—Subsec. (a). Puspan. L. 115–52, § 303(a)(1), substituted “fiscal year 2018” for “fiscal year 2013” in introductory provisions.

Subsec. (a)(1)(E). Puspan. L. 115–52, § 303(a)(2), added subpar. (E).

Subsec. (a)(2)(C). Puspan. L. 115–52, § 303(a)(3)(A), amended subpar. (C) generally. Prior to amendment, subpar. (C) related to publication of notice for fiscal years 2013 to 2017.

Subsec. (a)(2)(E)(i). Puspan. L. 115–52, § 303(a)(3)(B)(i), substituted “on the earlier of—” for “no later than”, inserted subcl. (I) designation before “the date”, substituted “; or” for period at end, and added subcl. (II).

Subsec. (a)(2)(E)(ii)(I). Puspan. L. 115–52, § 303(a)(3)(B)(ii), substituted “notice provided for in subparagraph (C)” for “notice provided for in clause (i) or (ii) of subparagraph (C), as applicable”.

Subsec. (a)(3). Puspan. L. 115–52, § 303(a)(4)(A), struck out “and prior approval supplement” after “application” in heading.

Subsec. (a)(3)(A). Puspan. L. 115–52, § 303(a)(4)(B), struck out “or a prior approval supplement to an abbreviated new drug application” after “application”.

Subsec. (a)(3)(B), (C). Puspan. L. 115–52, § 303(a)(4)(C), amended subpars. (B) and (C) generally. Prior to amendment, subpars. (B) and (C) related to notice for fiscal years 2013 to 2017 and fee due dates, respectively.

Subsec. (a)(3)(D). Puspan. L. 115–52, § 303(a)(4)(D), inserted in heading “, is withdrawn prior to being received, or is no longer received” after “received” and in text substituted cls. (i) and (ii) for “The Secretary shall refund 75 percent of the fee paid under subparagraph (A) for any abbreviated new drug application or prior approval supplement to an abbreviated new drug application that the Secretary considers not to have been received within the meaning of section 355(j)(5)(A) of this title for a cause other than failure to pay fees.”

Subsec. (a)(3)(E). Puspan. L. 115–52, § 303(a)(4)(E), struck out “or prior approval supplement” after “new drug application”.

Subsec. (a)(3)(F). Puspan. L. 115–52, § 303(a)(4)(F), substituted “2017” for “2012” and “subsection (d)(2)” for “subsection (d)(3)” in introductory provisions.

Subsec. (a)(4)(A). Puspan. L. 115–52, § 303(a)(5)(A)(i), substituted “in at least one generic drug submission that is” for “, or intended to be identified, in at least one generic drug submission that is pending or” in introductory provisions.

Subsec. (a)(4)(A)(i). Puspan. L. 115–52, § 303(a)(5)(A)(ii), substituted “in at least one generic drug submission that is” for “or intended to be identified in at least one generic drug submission that is pending or”.

Subsec. (a)(4)(A)(ii). Puspan. L. 115–52, § 303(a)(5)(A)(iii), substituted “is identified in at least one generic drug submission in which the facility is approved to produce one or more active pharmaceutical ingredients or in a Type II active pharmaceutical ingredient drug master file referenced in at least one such” for “produces, or which is pending review to produce, one or more active pharmaceutical ingredients identified, or intended to be identified, in at least one generic drug submission that is pending or approved or in a Type II active pharmaceutical ingredient drug master file referenced in such a”.

Subsec. (a)(4)(A)(iii). Puspan. L. 115–52, § 303(a)(5)(A)(i), (iv), substituted “in at least one generic drug submission that is” for “, or intended to be identified, in at least one generic drug submission that is pending or” and “only to the fee attributable to the manufacture of the finished dosage forms” for “to fees under both such clauses”.

Subsec. (a)(4)(C), (D). Puspan. L. 115–52, § 303(a)(5)(B), amended subpars. (C) and (D) generally. Prior to amendment, subpars. (C) and (D) related to notice and fee due date for fiscal years 2013 to 2017, respectively.

Subsec. (a)(5), (6). Puspan. L. 115–52, § 303(a)(6), (7), added par. (5) and redesignated former par. (5) as (6).

Subsec. (span)(1)(A). Puspan. L. 115–52, § 303(span)(1)(A), substituted “2018” for “2013” in heading and “2018” for “2013” and “$493,600,000” for “$299,000,000” in text and struck out at end “Of that amount—

“(i) $50,000,000 shall be generated by the one-time backlog fee for generic drug applications pending on October 1, 2012, established in subsection (a)(1); and

“(ii) $249,000,000 shall be generated by the fees under paragraphs (2) through (4) of subsection (a).”

Subsec. (span)(1)(B). Puspan. L. 115–52, § 303(span)(1)(B), substituted “2019 through 2022” for “2014 through 2017” in heading and “2019 through 2022” for “2014 through 2017”, “paragraphs (2) through (5)” for “paragraphs (2) through (4)”, and “$493,600,000” for “$299,000,000” in text.

Subsec. (span)(2). Puspan. L. 115–52, § 303(span)(2)(A), substituted “such paragraph for a fiscal year” for “paragraph (1)(A)(ii) for fiscal year 2013 and paragraph (1)(B) for each of fiscal years 2014 through 2017” and “through (5)” for “through (4)” in introductory provisions.

Subsec. (span)(2)(A). Puspan. L. 115–52, § 303(span)(2)(B), substituted “Five percent” for “Six percent”.

Subsec. (span)(2)(B), (C). Puspan. L. 115–52, § 303(span)(2)(C), amended subpars. (B) and (C) generally. Prior to amendment, subpars. (B) and (C) read as follows:

“(B) Twenty-four percent shall be derived from fees under subsection (a)(3) (relating to abbreviated new drug applications and supplements). The amount of a fee for a prior approval supplement shall be half the amount of the fee for an abbreviated new drug application.

“(C) Fifty-six percent shall be derived from fees under subsection (a)(4)(A)(i) (relating to generic drug facilities). The amount of the fee for a facility located outside the United States and its territories and possessions shall be not less than $15,000 and not more than $30,000 higher than the amount of the fee for a facility located in the United States and its territories and possessions, as determined by the Secretary on the basis of data concerning the difference in cost between inspections of facilities located in the United States, including its territories and possessions, and those located outside of the United States and its territories and possessions.”

Subsec. (span)(2)(D). Puspan. L. 115–52, § 303(span)(2)(D), substituted “Seven percent” for “Fourteen percent”, “$15,000” for “not less than $15,000 and not more than $30,000”, and “possessions.” for “possessions, as determined by the Secretary on the basis of data concerning the difference in cost between inspections of facilities located in the United States and its territories and possessions and those located outside of the United States and its territories and possessions.”

Subsec. (span)(2)(E). Puspan. L. 115–52, § 303(span)(2)(E), added subpar. (E).

Subsec. (c)(1). Puspan. L. 115–52, § 303(c)(1), substituted “2019” for “2014” and inserted “to equal the product of the total revenues established in such notice for the prior fiscal year multiplied” after “a fiscal year,” in introductory provisions and struck out concluding provisions which read as follows: “The adjustment made each fiscal year under this subsection shall be added on a compounded basis to the sum of all adjustments made each fiscal year after fiscal year 2013 under this subsection.”

Subsec. (c)(2). Puspan. L. 115–52, § 303(c)(2), substituted “2022” for “2017” in two places, substituted “the first 3 months of fiscal year 2023” for “the first 3 months of fiscal year 2018”, and struck out “Such fees may only be used in fiscal year 2018.” before “If such an adjustment”.

Subsec. (d)(1). Puspan. L. 115–52, § 303(d)(1), added par. (1) and struck out former par. (1) which related to setting fees for fiscal year 2013.

Subsec. (d)(2), (3). Puspan. L. 115–52, § 303(d), redesignated par. (3) as (2), substituted “fee under paragraph (1)” for “fees under paragraphs (1) and (2)” in introductory provisions, and struck out former par. (2) which related to setting fees for fiscal years 2014 through 2017.

Subsec. (e). Puspan. L. 115–52, § 905(span)(3), substituted “Limitations” for “Limit” in heading, designated existing provisions as par. (1) and inserted heading, and added par. (2).

Subsec. (f)(1). Puspan. L. 115–52, § 303(e)(3), substituted “paragraph (3)” for “paragraph (4)” and “Such information shall, for each fiscal year, be submitted, updated, or reconfirmed on or before June 1 of the previous fiscal year.” for “Such information shall—

“(A) for fiscal year 2013, be submitted not later than 60 days after the publication of the notice under paragraph (1); and

“(B) for each subsequent fiscal year, be submitted, updated, or reconfirmed on or before June 1 of the previous year.”

Puspan. L. 115–52, § 303(e)(1), (2), redesignated par. (2) as (1) and struck out former par. (1). Prior to amendment, text of par. (1) read as follows: “Not later than October 1, 2012, the Secretary shall publish in the Federal Register a notice requiring each person that owns a facility described in subsection (a)(4)(A), or a site or organization required to be identified by paragraph (4), to submit to the Secretary information on the identity of each such facility, site, or organization. The notice required by this paragraph shall specify the type of information to be submitted and the means and format for submission of such information.”

Subsec. (f)(2). Puspan. L. 115–52, § 303(e)(4)(A), (B), substituted “Information required to be submitted” for “Contents of notice” in heading and “paragraph (1)” for “paragraph (2)” in introductory provisions.

Puspan. L. 115–52, § 303(e)(2), redesignated par. (3) as (2). Former par. (2) redesignated (1).

Subsec. (f)(2)(A). Puspan. L. 115–52, § 303(e)(4)(C), struck out “or intended to be identified” after “facility identified”.

Subsec. (f)(2)(F). Puspan. L. 115–52, § 303(e)(4)(D)–(F), added subpar. (F).

Subsec. (f)(3), (4). Puspan. L. 115–52, § 303(e)(2), redesignated par. (4) as (3). Former par. (3) redesignated (2).

Subsec. (g)(1). Puspan. L. 115–52, § 303(f)(1), inserted at end “This paragraph shall cease to be effective on October 1, 2022.”

Subsec. (g)(2)(C)(ii). Puspan. L. 115–52, § 303(f)(2), substituted “of section 355(j)(5)(A)” for “of 355(j)(5)(A)”.

Subsec. (g)(5). Puspan. L. 115–52, § 303(f)(3), added par. (5).

Subsec. (h)(2). Puspan. L. 115–52, § 303(g), struck out “for Type II active pharmaceutical ingredient drug master files, abbreviated new drug applications and prior approval supplements, and generic drug facilities and active pharmaceutical ingredient facilities” after “in the rate,”.

Subsec. (i)(2)(A)(i). Puspan. L. 115–52, § 303(h)(1)(A), substituted “subparagraph (C)” for “subparagraphs (C) and (D)”.

Subsec. (i)(2)(C). Puspan. L. 115–52, § 303(h)(1)(B), (D), redesignated subpar. (D) as (C) and struck out former subpar. (C). Prior to amendment, text of subpar. (C) read as follows: “Until the date of enactment of an Act making appropriations through September 30, 2013, for the salaries and expenses account of the Food and Drug Administration, fees authorized by this section for fiscal year 2013 may be collected and shall be credited to such account and remain available until expended.”

Subsec (i)(2)(D). Puspan. L. 115–52, § 303(h)(1)(D), redesignated subpar. (D) as (C).

Puspan. L. 115–52, § 303(h)(1)(C), struck out “in subsequent years” after “payments” in heading and “(after fiscal year 2013)” after “fiscal year” in text.

Subsec. (i)(3). Puspan. L. 115–52, § 303(h)(2), substituted “fiscal years 2018 through 2022” for “fiscal years 2013 through 2017”.

Subsec. (o). Puspan. L. 115–52, § 303(i), added subsec. (o).

2012—Subsec. (a). Puspan. L. 112–193, § 2(span)(2), inserted “for such year” after “obligation of fees” wherever appearing.

Subsec. (i)(2)(C). Puspan. L. 112–193, § 2(span)(3), inserted comma after “September 30, 2013” and struck out comma after “for fiscal year 2013”.

Amendment by Puspan. L. 117–180 effective Oct. 1, 2022, with fees under this subpart to be assessed for all abbreviated new drug applications received on or after Oct. 1, 2022, see section 3005 of Puspan. L. 117–180, set out as a note under section 379j–41 of this title.

Amendment by section 303 of Puspan. L. 115–52 effective Oct. 1, 2017, with fees under this subpart to be assessed for all abbreviated new drug applications received on or after Oct. 1, 2017, see section 306 of Puspan. L. 115–52, set out as a note under section 379j–41 of this title.

Section ceases to be effective Oct. 1, 2027, see section 3004(a) of Puspan. L. 117–180, set out as a note under section 379j–41 of this title.

Section effective Oct. 1, 2012, with fees under this section and section 379j–41 of this title to be assessed for all human generic drug submissions and Type II active pharmaceutical drug master files received on or after Oct. 1, 2012, see section 305 of Puspan. L. 112–144, set out as a note under section 379j–41 of this title.

Puspan. L. 112–193, § 2(c), Oct. 5, 2012, 126 Stat. 1443, provided that: